Lv1
58 积分 2025-04-29 加入
Pathophysiology and therapeutic options for cirrhotic portal hypertension
11天前
已完结
Network Meta‐Analysis: Comparison of Pharmacological Therapies in Compensated Metabolic Dysfunction‐Associated Steatohepatitis Cirrhosis for Fibrosis Regression and MASH Resolution
15天前
已关闭
Meta‐Analysis: Global Prevalence and Mortality of Cirrhosis in Metabolic Dysfunction‐Associated Steatotic Liver Disease
16天前
已完结
Recompensation in cirrhosis: unravelling the evolving natural history of nonalcoholic fatty liver disease
17天前
已完结
Global Prevalence of Advanced Liver Fibrosis and Cirrhosis in the General Population: A Systematic Review and Meta-analysis
17天前
已完结
Recompensation in cirrhosis: unravelling the evolving natural history of nonalcoholic fatty liver disease
17天前
已完结
Natural history and progression of metabolic dysfunction-associated steatotic liver disease
17天前
已完结
Combination therapies for metabolic dysfunction-associated steatohepatitis: challenges and opportunities
1个月前
已完结
Metabolic Dysfunction–Associated Steatotic Liver Disease in Adults
2个月前
已完结
Long-term prognosis of lean MASLD: evidence from three population-based prospective cohorts
3个月前
已关闭
皖公网安备34019202002308
